Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 13Terminated 7Recruiting 5Active not recruiting 4Withdrawn 2Unknown 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Melanoma 2Lung Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Lymphoma 1Histiocytic Sarcoma 1Head and Neck Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Dendritic Cell Sarcoma, Follicular 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2Antibodies, Monoclonal 2sargramostim 1prednylidene 1pembrolizumab 1glucarpidase 1deltacortene 1brincidofovir 1Specimen Handling 1Rituximab 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Methods 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunotherapy, Active 1Immunization, Passive 1Health Care Economics and Organizations 1Etoposide 1Drug Therapy 1Coal Tar 1Brentuximab Vedotin 1Biopsy 1Biomarkers 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Lymphoma × pembrolizumab × Clear all
NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡